Journal of agricultural medicine and community health (농촌의학ㆍ지역보건)

Korean Society for Rural Medicine and Community Health (한국농촌의학지역보건학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of COVID-19 vaccinations on deaths of the COVID-19 cases in some elderly long-term care facilities, Gwangju

광주광역시 요양시설 코로나19 집단 발생 사례에서 코로나19 백신 접종에 의한 사망 예방 효과

  • Ryu, So Yeon (Department of Preventive Medicine, College of Medicine, Chosun University) ;
  • Cho, Jun Hwi (Gwangju Center for Infectious Diseases Control and Prevention) ;
  • Lee, Ran (Gwangju Center for Infectious Diseases Control and Prevention) ;
  • Park, So Yeong (Gwangju Center for Infectious Diseases Control and Prevention) ;
  • Jung, Daun (Gwangju Center for Infectious Diseases Control and Prevention) ;
  • Bae, So Hyun (Gwangju Center for Infectious Diseases Control and Prevention) ;
  • Ko, HwaPyeong (Infectious Diseases Control Division, Gwangju City Hall)
  • 류소연 (조선대학교 의과대학 예방의학교실) ;
  • 조준휘 (광주광역시 감염병관리지원단) ;
  • 이란 (광주광역시 감염병관리지원단) ;
  • 박소영 (광주광역시 감염병관리지원단) ;
  • 정다운 (광주광역시 감염병관리지원단) ;
  • 배소현 (광주광역시 감염병관리지원단) ;
  • 고화평 (광주광역시청 감염병관리과)
  • Received : 2022.05.13
  • Accepted : 2022.06.07
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The purpose of this study was to identify the effectiveness of COVID-19 vaccinations on deaths of the COVID-19 cases in some elderly long-term care facilities (LTCF) in Gwangju Metropolitan City. Methods: The study subjects were 659 COVID-19 cases in residents of 7 elderly LTCF, Gwangju, from 21 Dec. 2021 to 28 Jan. 2022. The used variables were confirmed dates for COVID-19, demographic characteristics, co-morbidities, presentation of symptoms, death and vaccination related characteristics including type of vaccine, doses and dates. Vaccination status were classified as not vaccinated, partially and fully vaccinated. The associations of vaccination status and deaths of COVID-19 cases were tested by chi-square test and multiple logistic regression analysis. Results: The rates of not vaccinated, partially vaccinated and fully vaccinated were 19.4%, 10.2% and 70.4%, respectively. The mortality rate of the cases was 6.4%. The death rate by vaccination status was 16.4% in not vaccinated, 15.4% in partially vaccinated and 2.6% in fully vaccinated, showing a statistically significant difference. The adjusted odds ratios (ORs) (95% confidence intervals, CIs) of death compared to fully vaccinated were 7.64 (3.87-16.34) in non-vaccinated, and 6.97 (3.44-14.14) in partially vaccinated. Conclusions: COVID-19 vaccination seems to work effectively in preventing deaths of COVID-19 cases of elderly LTCF residents. This finding support that fully vaccinations in high risk group such as elderly LTCF residents is very important for one of strategies of COVID-19 management.

Keywords

References

  1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [cited 2022 April 15]. Available at https://www.who.int/director-gegreal-s-opening-remakrs-at-the-media-briefing-on-covid-19---11-march-2020
  2. World Health Organization. WHO COVID-19 Dashboard. Situation by Region, Country, Territory and Area - 11 April 2022 [cited 2022 April 15]. Available at https://covid19.who.int/table
  3. Korea Disease Control and Prevention Agency. Coronavirus Disease 2019 (COVID-19) Dashboard [Internet]. Cheongju: Korea Disease Control and Prevention Agency [cited 2022 April 15]. Available at http://ncov.mohw.go.kr/ (Korean)
  4. Korea Disease Control and Prevention Agency. COVID-19 vaccines [Internet]. Cheongju: Korea Disease Control and Prevention Agency [cited 2022 April 15]. Available from: http://ncv.kdca.go.kr/ (Korean)
  5. Ahn SH, Lee SH. Updates on Coronavirus Disease 19 Vaccine and Its Clinical Application. Korean J Fam Pract 2021;11(4):236-246 (Korean) https://doi.org/10.21215/kjfp.2021.11.4.236
  6. Polack EP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Freck Jr RW, Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, for the C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27):2603-2315. https://doi.org/10.1056/NEJMoa2034577
  7. Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 patients requiring mechanical ventilation following implementation of a National COVID-19 Vaccination Program-Israel, December 2020-February 2021. MMWR 2021;70(9):326-328
  8. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, Mcneal T, Ghamande S, Douin DJ, Talbot K, Casey JD, Mohr NM, Zepeski A, Shapiro NI, Gibbs KW, Files C, Hager DN, Shehu A, Prekker ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning DJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, ten Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Halasa N, Chappel JD, Lauring AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Rhoads J, Lindsell CJ, Hart KW, Zhu Y, Olson SM, Kobayashi M, Verani JR, Patel MM, for the Influenza and Other Viruses in the Acutely III (IVY) Network. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 2021;326(20): 2043-2053 https://doi.org/10.1001/jama.2021.19499
  9. Thomas SJ, Moreira ED jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Polack FP, Zerbini C, Bailey R, Swangson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW jr, Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Gruber WC, Jansen KU, for the C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 2021; 385(19):1761-1773. http://doi.org/10.1056/NEJMoa2110345
  10. Saban M, Myers V, Wilf-Miron R. Chanages in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten monthes into the vaccination program: The Israeli case. Prev Med 2022;154:1-8. https://doi.org/10.1016/j.ypmed.2021.106890
  11. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, Walker AS, Peto TEA. Effect of Covid-19 vaccination on transmission of alpha and delta variants. N Engl J Med 2022. https://doi.org/10.1016/NEJMoa2116597
  12. Kim JA, Kim YY, Kim RK, Lee SJ, Park YJ, Yeom HS, Kim SS. Effectiveness of COVID-19 vaccines in preventing severity and mortality, May to July, 2021. Public Health Weekly Report 2021;14(37):2612-2615 (Korean)
  13. World Health Organization. Tracking SARSCoV-2 variants [Internet]. [cited 2022 April 15]. Available at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
  14. Ryu B, Oh J, Shin M, Kim S, Kim I. Global trends and characteristics of the SARS-CoV-2 delta variant. Public Health Weekly Report 2021;14(33):2354-2362 (Korean)
  15. Woo I, Ahn H, Im H, Park H, Kim B, Kim S Lee y. Updates of research trends for COVID-19 vaccine on SARS-CoV-2 omicron variant. Public Health Weekly Report 2022;15(9):556-563 (Korean)
  16. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T, Crook D, Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Screaton GR; Com-COV2 study group. Reduced neutralization of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet 2022;399(10321):234-236. doi: https://doi.org/10.1016/S0140-6736(21)02844-0
  17. Kim OS, Jeong SY, Kim JY, So YR. Status of infection control and educational needs of nurses in long term care facilities in Korea. Korean J Rehabil Nurs 2018;21(1):1-11 (Korean) https://doi.org/10.7587/kjrehn.2018.1
  18. McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, Lewis J, Baer A, Kawakami V, Lukoff MD, Ferro J, Brostrom-Smith C, Rea TD, Sayre MR, Riedo FX, Russel D, Hiatt B, Montgomery P, Rao AK, Chow EJ, Tobolowsky F, Hughes MJ, Bardossy AC, Oakley LP, Jacobs JR, Stone ND, Reddy SC, Jernigan JA, Honein MA, Clark TA, Duchin JS, for the Public Health-Seattle and King County, Evergreen Health, and CDC COVID-19 Investigation Team. N Eng l Med 2020;382(22):2081-90. https://doi.org/10.1056/NEJMoa2005412 PMID: 3232997
  19. ECDC Public Health Emergency Team, Danis K, Fonteneau L, Goerges S, DaniauC, Bernard-Stoecklin S, Domegan L, O'Donnell J, Hauge SH, Dequeker S, Vandael E, Heyden JV, Renard F, Sierra NB, Ricchizzi E, Scheickert B, Schmidt N, Sin MA, Eckmanns T, Paiva J, Schneider E. High impact of COVID-19 in long-term care facilities, suggestion for monitoring in the EU/EEA, May 2020. Euro Surveil. 2020;25(22):pii=2000956. https://doi.org/10.2807/1560-7917.ES.2020.25.22.2000956
  20. Jang J, Kim Y, Kim YY, Yeon H, Hwang I, Park K, Park Y, Lee S, Kwon D. Coronavirus Disease-19 (COVID-19) one-year outbreak major cluster infection report as of January 19, 2021, in the Republic of Korea. Public Health Weekly Report 2021;14(9):482-495 (Korean)
  21. Oh J, Park K. Severity and case fatality rates according to Covid-19 vaccination history of Covid-19 confirmed inpatients of nursing hopitals in Gyeonggi province, Spetember-October, 2021. Public Health Weekly Report 2022;15(5):305-312 (Korean)
  22. Mazagatos C, Monge S, Olmedo C, Vega L, Gallego P, Martin-Merino E, Sierra MJ, Limia A, Larrauri A, Working Group for the surveillance and control of COVID-19 in Spain. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalizations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. Euro Surveill 2021;26(24):pii=2100452. https://doi.org/10.2807/1560-7917.ES.2021.26.24.2100452
  23. Park H, Lee J, Choi J, Lee H, Yoo M, Song Y, Lee S, Park Y, Yoo J, Kim E, Son T, Kim S, Kim Y, Park S, Yoo H, Nam S. Comparisons of attack rates and case fatality rates for clusters of long-term care facilities infected with Delta versus Omicron COVID-19 variants. Public Health Weekly Report 2022;15(16):1010-1017 (Korean)
  24. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, Han J, McEvoy C, Ong TC, Naleway AL, Reese SE, Embi PJ, Dascomb K, Klein NP, Griggs EP, Konatham D, Kharbanda AB, Yang DH, Fadel WF, Grisel N, Goddard K, Patel P, Liao I, Birch R, Valvi NR, Reynolds S, Arndorfer J, Zerbo O, Dickerson M, Murthy K, Williams J, Bozio CH, Blanton L, Verani JR, Schrag SJ, Dalton AF, Wondimu MH, Link-Gelles R, Azziz-Baumgartner E, Barron MA, Gaglani M, Thompson MG, Fireman B. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19 associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISIONNetwork, 10 States, August 2021-January 2022. Morbid Mortal Wkly Rep 2022;71(7):255-263 https://doi.org/10.15585/mmwr.mm7107e2
  25. Accorsi EK, Britton A, Fleming-Dutra K, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA 2022;327(7):639-651 https://doi.org/10.1001/jama.2022.0470
  26. Nemet I, Kliker L, Lustig Y, Zukerman N, Erster O, Cohen C, Kreiss Y, Alroy-Preis S, Regev-Yochay G, Mendelson E, Mandelboim M. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med 2022;386(5). https://doi.org/10.1056/NEJMc2119358
  27. Gwangju Center for Infectious Diseases Control and Prevention. 2021 COVID-19 in Gwangju FACT SHEET [Internet]. Gwangju:GCIDC [cited 2022 May 2]. available at http://gcidc.or.kr/diam/web/index.html?contentId=357a6fdf7642bf815a88822c447d9dc4 (Korean)
  28. Korea Disease Control and Prevention Agency. Coronavirus Disease 2019 (COVID-19) Dashboard - 11 April 2022 [Internet]. Cheongju: Korea Disease Control and Prevention Agency [cited 2022 April 15]. Available at http://ncov.mohw.go.kr/bdBoardList_Real.do?brdId=1&brdGubun=11&ncvContSeq=&contSeq=&board_id=&gubun= (Korean)
  29. Kim SH. Characteristics and outcomes of the Korean patients with coronavirus disease 2019; analyses of the national database. Allergy Asthma Respir Dis 2021;9(3):113-114. https://doi.org/10.4168/aard.2021.9.3.113